Search results
Showing 951 to 1000 of 3030 results for all
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
View recommendations for TA160Show all sections
This quality standard covers assessing and managing trauma (complex fractures, non-complex fractures, major trauma and spinal injury) in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS166Show all sections
Sections for QS166
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.
Ustekinumab for treating moderate to severe plaque psoriasis (TA180)
Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).
Leriglitazone for treating cerebral adrenoleukodystrophy in people 2 years and over [ID3903]
In development Reference number: GID-HST10069 Expected publication date: 11 April 2027
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Immunosuppressive therapy for kidney transplant in children and young people (TA482)
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).
Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia. This involves using radiofrequency (heat) energy to destroy the abnormal cells and promote the growth of healthy normal cells.
Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.
use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the following arrangements are in place: - coordination of...
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)
Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development Reference number: GID-TA10089 Expected publication date: 15 November 2017
Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.
Show all sections
Hybrid procedure for interim management of hypoplastic left heart syndrome in neonates (HTG158)
Evidence-based recommendations on hybrid procedure for interim management of hypoplastic left heart syndrome in neonates. This involves placing bands around the branches of the pulmonary artery and inserting stents to keep the ductus arteriosus open.
View recommendations for HTG158Show all sections
Sections for HTG158
Deep brain stimulation for intractable trigeminal autonomic cephalalgias (HTG252)
Evidence-based recommendations on deep brain stimulation for intractable trigeminal autonomic cephalalgias. This involves delivering electrical impulses to a precise area of the brain using an electrode to mask the pain.
View recommendations for HTG252Show all sections
Sections for HTG252
Extracorporeal albumin dialysis for acute liver failure (HTG202)
Evidence-based recommendations on extracorporeal albumin dialysis for acute liver failure. This involves using a dialysis machine to remove both water-soluble toxins and toxins that are attached to albumin and accumulate in liver failure.
View recommendations for HTG202Show all sections
Sections for HTG202
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
Interim methods guide for developing good practice guidance (PMG15)
This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.
Implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache (HTG378)
Evidence-based recommendations on implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache. This involves implanting a device into the cheek to stimulate a group of nerves called the sphenopalatine ganglion.
Radiofrequency ablation for gastric antral vascular ectasia (HTG373)
Evidence-based recommendations on radiofrequency ablation for gastric antral vascular ectasia. This involves using radiofrequency (heat) energy to stop the bleeding by destroying the enlarged blood vessels.
Evidence-based recommendations on artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure. This involves replacing the 2 lower chambers of the heart with a mechanical device to improve circulation until heart transplantation.
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (HTG410)
Evidence-based recommendations on balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension in adults. This involves inserting and inflating a balloon in blocked blood vessels in the lungs to improve blood flow.
Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.
Evidence-based recommendations on capivasertib (Truqap) with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment in adults.
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (HTG438)
Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy.
Photorefractive (laser) surgery for the correction of refractive errors (HTG107)
Evidence-based recommendations on photorefractive (laser) surgery for the correction of refractive errors. This involves using a special laser to permanently change the shape of the cornea.
View recommendations for HTG107Show all sections
Sections for HTG107
Sacrocolpopexy using mesh to repair vaginal vault prolapse (HTG444)
Evidence-based recommendations on sacropolpopexy using mesh to repair vaginal vault prolapse in women. This involves attaching mesh, usually from the top of the vagina to the base of the spine, to support the pelvic organs.
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.
Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.
View recommendations for TA161Show all sections
Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.
Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique) (HTG29)
Evidence-based recommendations on complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique). This involves complete surgical tumour removal with intraoperative heated chemotherapy, and is followed by postoperative intraperitoneal chemotherapy.
View recommendations for HTG29Show all sections
Sections for HTG29
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Suspected sepsis in people aged 16 or over: recognition, assessment and early management (NG253)
This guideline covers the recognition, diagnosis and early management of suspected sepsis in people aged 16 or over who are not and have not recently been pregnant. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
End of life care for infants, children and young people (QS160)
This quality standard covers end of life care for infants, children and young people (from birth to 18 years) who have a life-limiting condition. Life-limiting conditions are those that are expected to result in an early death for the person. It also covers support for family members and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS160Show all sections
Sections for QS160
- Quality statements
- Quality statement 1: Advance care plan
- Quality statement 2: Named medical specialist
- Quality statement 3: Emotional and psychological support
- Quality statement 4: Specialist paediatric palliative care team
- Quality statement 5: Support for grief and loss for parents or carers
- Quality statement 6: Care at home
- About this quality standard
Interim clinical guideline surveillance process and methods guide 2013 (PMG16)
This guide outlines the main elements of the interim NICE clinical guideline surveillance process and methodology, which was agreed by the NICE Board in July 2013
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.
NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers. Your involvement is highly valued. We are guided by your knowledge and experience.
NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers. Your involvement is highly valued. We are guided by your knowledge and experience.
Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)
Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults.
Evidence-based recommendations on lusutrombopag (Mulpleo) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.